Cargando…
PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies
Expression of protein arginine methyltransferase 5 (PRMT5) is highly positively correlated to DNA damage repair (DDR) and DNA replication pathway genes in many types of cancer cells, including ovarian and breast cancer. In the current study, we investigated whether pharmacologic inhibition of PRMT5...
Autores principales: | Carter, Jack, Hulse, Michael, Sivakumar, Monisha, Burtell, Jessica, Thodima, Venkat, Wang, Min, Agarwal, Anjana, Vykuntam, Komali, Spruance, Jacob, Bhagwat, Neha, Rager, Joseph, Ruggeri, Bruce, Scherle, Peggy, Ito, Koichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627093/ https://www.ncbi.nlm.nih.gov/pubmed/37861290 http://dx.doi.org/10.1158/2767-9764.CRC-23-0070 |
Ejemplares similares
-
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
por: Brown-Burke, Fiona, et al.
Publicado: (2023) -
Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells
por: Dominici, Claudia, et al.
Publicado: (2021) -
The PRMT6/PARP1/CRL4B Complex Regulates the Circadian Clock and Promotes Breast Tumorigenesis
por: Yang, Tianshu, et al.
Publicado: (2023) -
PRMT1 loss sensitizes cells to PRMT5 inhibition
por: Gao, Guozhen, et al.
Publicado: (2019) -
Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma
por: Sloan, Shelby L., et al.
Publicado: (2021)